Capital Markets Day BRAIN Biotech AG: Focus on BEC Technology and its Transformational Potential
BRAIN Biotech sees significant commercial potential in its proprietary genome editing technology, BRAIN Engineered CAS (BEC). This technology platform has good prospects to contribute to dynamic revenue growth in the service business (TMS) as a "We CRISPR for you" service. In addition, BEC will accelerate proprietary developments from BRAIN's incubator, be used to develop highly efficient microbiological production strains, and offer the opportunity to build-up a lucrative licensing business.
Given the importance of BEC for the development of the company, the first step will be to create a flexible unit within BRAIN Biotech AG that will focus exclusively on the further development and partnering of this genome editing technology. In a second step, the technology will be carved out into a separate company. This will allow for maximum agility in research and enable flexible financing alternatives along the expansion path on the range of applications.
Lukas Linnig, CFO BRAIN Biotech AG, states: "The BEC technology is based on a proprietary CRISPR-Cas9-independent nuclease and can be employed for precise genome editing. With this proprietary development, BRAIN achieves freedom to operate from existing patents and can therefore use this technology cost-effectively for its own developments as well as aim to develop a profitable licensing business. In addition, we use BEC in service activities for our customers. Our proprietary genome editing nuclease enables BRAIN to actively participate in a market with strong growth and great influence on a sustainable biology based industrial production."
Looking for additional strategic cooperation partners
In addition to the exclusive partnership for the use of the BEC technology in plants and the development in the field of life sciences announced in July together with Sartorius, BRAIN Biotech is actively striving for a partnering strategy in order to develop new fields of application, such as health care or diagnostics. Adriaan Moelker, CEO of BRAIN Biotech AG, says: "Strong partners are essential for us to quickly and purposefully introduce new applications and products to the market which are based on our BEC. We will carefully consider when to partner to ensure that all of BRAIN's stakeholders can participate in BEC's economic potential to the full extend."
CRISPR-Cas genome editing nucleases can be used to modify genetic material in cells by specifically altering genes and inserting them into the genome or removing them altogether. Scientists use this biotechnological gene-editing process to make plants more resistant to pests or drought, for example, or to produce biological fuels. In biopharmaceuticals, gene scissors can lead to new therapies and improve the chances of curing a wide range of diseases such as cancer, neurodegenerative or hereditary diseases. Genome editing also has a wide range of applications in industrial biotechnology. Industry and academia alike are benefiting from an increasing variety of available genome editing tools.
The recorded presentations on the CMD 2021 can be found on the BRAIN Biotech website: https://www.brain-biotech.com/investors/capital-markets-day ?
Please find the press photo for download in the press area on our website:https://www.brain-biotech.com/press
Picture: The ongoing pandemic restrictions had led BRAIN Biotech to prefer a virtual only CMD format. CEO Adriaan Moelker (top left), CFO Lukas Linnig (bottom right) and the scientific heads of the genome editing program, Dr. Michael Krohn (top right) and Dr. Paul Scholz (bottom left), explained the opportunities which genome editing offers and how BRAIN Biotech's genome editing tool BEC differs. (c) BRAIN Biotech AG ?
BRAIN Biotech AG ("BRAIN") is a leading European specialist in industrial biotechnology. As a technology provider and developer of bio-based products and solutions for nutrition, health and the environment, the company supports the biologization of industry and contributes to a more sustainable economy. BRAIN is the parent company of the BRAIN Group. Two pillars form BRAIN Group's business: The BioScience segment includes contract research for renowned industrial partners as well as an incubator for the development of the company's own highly innovative products. In the BioIndustrial segment, the company focuses on specialty business in the production and refinement of enzymes, microorganisms and bioactive natural products and the respective distribution. The BRAIN Group maintains its own diverse collection of natural resources: the BRAIN Bioarchive comprises microorganisms, genetic material and natural substances. Based on this collection and with a comprehensive technology portfolio, BRAIN addresses technological challenges and develops bio-based products and solutions that are already successfully employed in the industry. The BRAIN Group has its own production facilities in Germany, UK and the US, which together with the associated biotechnological production expertise, complete the value chain within the Group. As a Participant of the United Nations Global Compact, BRAIN Biotech AG is committed to aligning strategies and operations with universal principles on human rights, labour, environment and anti-corruption, and take actions that advance societal goals. Since its IPO in 2016, BRAIN Biotech AG has been listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394). ?
Contact Investor Relations Michael Schneiders Head of Investor Relations & Sustainability Phone: +49 6251 9331-86 Email: email@example.com
Media Contact Dr. Stephanie Konle PR & Corporate Communications Phone: +49 6251 9331-70 Email: firstname.lastname@example.orgDisclaimer This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance by, and future developments at, BRAIN Biotech AG and the BRAIN Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors. BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.
Follow BRAIN Biotech on Twitter (@BRAINbiotech) and on LinkedIn (@BRAIN AG)
03.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.deLanguage: English Company: BRAIN Biotech AG Darmst?dter Stra?e 34-36 64673 Zwingenberg
Germany Phone: +49 (0) 62 51 / 9331-0 Fax: +49 (0) 62 51 / 9331-11 E-mail: email@example.com Internet: www.brain-biotech.com ISIN: DE0005203947 WKN: 520394 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1231015 ? End of News DGAP News Service